Industry Daily Summary
Industry Daily Summary: What Happened on October 16, 2026
AstraZeneca and insitro sign AI drug-discovery deal worth up to $1.5 billion
Lakefront sold five preclinical CAR-T programs to Armed Cell as Mankind Pharma agreed to take a 70% stake in the buyer.
-
P
Today in brief
AstraZeneca and insitro signed a drug-discovery deal for MASH and cardiomyopathies, with about $1.46 billion in potential milestone payments.12 Lakefront sold five preclinical CAR-T assets to Armed Cell for €8 million upfront. Mankind Pharma agreed to buy 70% of Armed Cell for €48 million.3
AstraZeneca and insitro target liver and heart diseases with AI partnership
AstraZeneca and insitro will use insitro’s AI platform to identify targets and develop potential medicines for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies.12 AstraZeneca will pay $40 million upfront and could owe about $1.46 billion in development and commercial milestones for exclusive worldwide rights to selected programs.12
insitro may also receive single-digit royalties on sales if a program reaches the market.12 The company says its Virtual Human platform analyzes human and cellular data to identify disease biology and possible causal drivers.12
AstraZeneca will lead clinical development and regulatory work on selected programs, while insitro advances targets toward development candidates.2 The programs remain at the discovery stage, with no candidate or clinical data disclosed.2
The partnership adds MASH discovery work to AstraZeneca’s existing effort in the disease, including AZD2389, a small-molecule inhibitor in Phase II testing.1 AstraZeneca discontinued another MASH candidate, AZD2693, after weak Phase II results.1
Lakefront sells five CAR-T programs as Mankind takes control of Armed Cell
Lakefront Biotherapeutics sold five preclinical CAR-T assets to Armed Cell Therapeutics for €8 million upfront.3 Mankind Pharma separately agreed to pay €48 million for a 70% stake in Armed Cell.3
Lakefront could receive up to $230 million in regulatory and commercial milestone payments, plus a low-single-digit royalty on sales.3 Armed Cell said the portfolio includes lead candidates for non-Hodgkin lymphoma and small-cell lung cancer.3
Armed Cell said the CAR-T designs use multiple targets intended to limit cancer cells’ ability to evade recognition, along with human-protein payloads meant to support immune-cell persistence and activity in tumors.3 All five assets remain preclinical. Lakefront has not announced when they might enter human trials.3
The assets originated at Galapagos, which changed its name to Lakefront in May after pursuing a spinout of its cell-therapy programs.45 Lakefront is also developing gamgertamig, a T-cell engager for autoimmune disease, and expects registrational studies to start in 2027.3
Also worth knowing
-
Evotec named Joanna Holbrook chief scientific officer, effective November 1. AL-S Pharma now aims to start a Phase 3 trial of AP-101 in 2027, later than its earlier target of late 2026. Sibylla Biotech, Integra Therapeutics, and TETRAPHARM also announced leadership changes.6